Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer

被引：0
|
作者：
Ghosh, Jaya [1 ]
Kumar, Lalit [1 ]
机构：
[1] All India Inst Med Sci, Dept Med Oncol, New Delhi 110029, India
来源：
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY | 2008年 / 29卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7 / U37
页数：4
相关论文
共 50 条
  • [41] Delta tocotrienol in recurrent ovarian cancer. A phase II trial
    Thomsen, Caroline Brenner
    Andersen, Rikke Fredslund
    Steffensen, Karina Dahl
    Adimi, Parvin
    Jakobsen, Anders
    [J]. PHARMACOLOGICAL RESEARCH, 2019, 141 : 392 - 396
  • [42] Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer
    Hussain, MM
    Kotz, H
    Minasian, L
    Premkumar, A
    Sarosy, G
    Reed, E
    Zhai, SP
    Steinberg, SM
    Raggio, M
    Oliver, VK
    Figg, WD
    Kohn, EC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) : 4356 - 4363
  • [43] A phase II study of single agent gemcitabine in recurrent epithelial ovarian cancer
    Tay, SK
    Tan, PK
    Wong, L
    Wong, CB
    [J]. 7TH BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY, 1999, : 317 - 321
  • [44] A phase II study of atezolizumab in combination with bevacizumab in patients with recurrent, persistent or metastatic cervical cancer
    Friedman, C. F.
    Snyder, A.
    Sharon, E.
    De Meritens, A. Buckley
    Cantrell, L. A.
    Corr, B. R.
    Konner, J.
    Konstantinopoulos, P. A.
    Soldan, K.
    Aghajanian, C. A.
    Zamarin, D.
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 154 : 17 - 18
  • [45] Predictive value of serum CA125 levels in women with persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) treated with bevacizumab (Bev) on a Gynecologic Oncology Group (GOG) phase II trial
    Randall-Whitis, L.
    Burger, R. A.
    Sill, M.
    Monk, B. J.
    Buening, B.
    Sorosky, J. I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] HEXAMETHYLMELAMINE CHEMOTHERAPY FOR PERSISTENT OR RECURRENT EPITHELIAL OVARIAN-CANCER
    MOORE, DH
    FOWLER, WC
    JONES, CP
    CRUMPLER, LS
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 165 (03) : 573 - 576
  • [47] Weekly topotecan in the treatment of recurrent and persistent epithelial ovarian cancer
    Safra, Tamar
    Inbar, Moshe
    Menczer, Joseph
    Grisaro, Dan
    Glezerman, Marek
    Levy, Tally
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 136 - 136
  • [48] The effect of bevacizumab maintenance therapy on survival in recurrent epithelial ovarian cancer
    Bakir, Mehmet Sait
    Birge, Ozer
    Karadag, Ceyda
    Dogan, Selen
    Tuncer, Hasan Aykut
    Simsek, Tayup
    [J]. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2021, 42 (06) : 1198 - 1204
  • [49] EFFECTIVENESS OF BEVACIZUMAB IN PLATINUM-RESISTANT RECURRENT EPITHELIAL OVARIAN CANCER
    Pinto, R.
    Monteiro, S.
    Lima, B.
    Lopes, A. R.
    Abreu, M.
    Ferreira, M.
    Sousa, S.
    Redondo, P.
    Pereira, D.
    Savva-Bordalo, J.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A271 - A271
  • [50] A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy
    Wenham, Robert M.
    Lapolla, James
    Lin, Hui-Yi
    Apte, Sachin M.
    Lancaster, Johnathan M.
    Judson, Patricia L.
    Gonzalez-Bosquet, Jesus
    Herschberger, Amber
    Havrilesky, Laura J.
    Secord, Angeles Alvarez
    [J]. GYNECOLOGIC ONCOLOGY, 2013, 130 (01) : 19 - 24
12345